A doctor never looked at the prescription. That’s the point. Utah has approved a pilot program that allows an AI system to issue initial acne prescriptions without any prior physician review, making it the first sanctioned autonomous prescribing system in the United States. It’s a small indication of something much larger happening in healthcare AI right now.
The system was built by Nolla Health, a New York-based health tech company. Patients using the Nolla Derm app complete a 10-to-15-minute intake questionnaire and a facial scan. The AI then assesses their skin and selects a treatment from a fixed list of physician-approved topical options. It does not generate novel treatment regimens. When the system lacks sufficient confidence, it passes the case to a licensed physician. According to the company, doctors agree with its recommendations in more than 96 percent of real-world cases, with disagreements typically involving dosage tweaks rather than entirely different treatments. That figure comes from Nolla itself and has not been independently verified.
The rollout is structured in stages. For the first 100 patients, a physician approves every prescription before it goes out. From patients 101 to 500, the AI prescribes autonomously while a physician reviews decisions daily after the fact. Beyond that, doctors audit a sample of prescriptions just once a week. It’s a graduated handoff, and the design reflects real regulatory caution.
The pilot runs under Utah’s Office of Artificial Intelligence Policy, which has established a framework specifically for testing AI applications in regulated industries. That regulatory context matters. Most states have no comparable mechanism, which means this kind of experiment would be legally impossible elsewhere in the U.S. right now. Utah is essentially acting as a sandbox for autonomous healthcare AI, and the outcome of this pilot will likely influence how other states think about similar programs.
The distinction from standard telehealth is worth being clear about. Companies like Hims, Keeps, and Ro have built large businesses using software to gather patient information, but a licensed clinician still makes the final call on every prescription. Nolla’s model is designed to remove that human step entirely, within defined constraints. That’s a different category of product.
The technical stack includes vision transformers and multimodal machine learning trained on more than 3 million labeled clinical cases. For the acne pilot specifically, the system is restricted to a short list of topical treatments and predefined pathways. Patients can choose home delivery or pharmacy pickup, and the app tracks skin changes daily with monthly treatment reviews. The service costs $4.99 per month. The app has been downloaded over 175,000 times across 44 states, but autonomous prescribing is currently only available to adults in Utah.
So does this matter? Yes, but not because acne treatment is high-stakes medicine. It matters because this is the first time a U.S. regulatory body has formally sanctioned an AI to make a prescribing decision without a human in the loop at the point of decision. That’s the precedent being set here, and the conditions under which it holds or breaks down will shape what comes next.
